Bristol-Myers Squibb Co. Analyst Notes On April 22, 2014, Bristol-Myers Squibb Co. (Bristol-Myers) and Samsung BioLogics (Samsung) jointly announced that they will increase the scope of their existing manufacturing agreement under which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its Incheon manufacturing site. Bristol-Myers and Samsung signed their first manufacturing agreement in July 2013 to collaborate in the production of a single commercial antibody cancer drug substance. Bristol-Myers Squibb Co (NYSE:BMY) shares after opening at $50.89 moved to $51.22 on last trade day and at the end of the day closed at $50.36. Company price to sales ratio in past twelve months was calculated as 5.09 and price to cash ratio as 18.44. Bristol-Myers Squibb Co (NYSE:BMY) showed a negative weekly performance of -0.30%.
Equities researchers at Citigroup Inc. raised their price target on shares of Pfizer (NYSE:PFE) from $31.00 to $36.00 in a research report issued on Monday, StockRatingsNetwork reports. Citigroup Inc.’s target price points to a potential upside of 12.36% from the company’s current price. Pfizer Inc. (NYSE:PFE) shares advanced 4.20% in last trading session and ended the day on $32.04. PFE return on equity ratio is recorded as 52.60% and its return on assets is 23.20%. Pfizer Inc. (NYSE:PFE) yearly performance is 9.99%.
AstraZeneca PLC has twice spurned Pfizer’s Inc.’s takeover efforts, but the maker of Viagra and Lipitor is hoping the third time may prove to be the charm. Pfizer said Monday that a proposed $100 billion acquisition may make sense for shareholders of both companies and that it is considering its next steps in its pursuit. AstraZeneca plc (ADR) (NYSE:AZN) shares moved up 12.16% in last trading session and was closed at $77.01, while trading in range of $73.85-$79.90. AstraZeneca plc (ADR) (NYSE:AZN) year to date performance is 33.44%.
Johnson & Johnson’s diabetes portfolio continues to grow apace with the news that its combination treatment Vokanamet has been approved in the EU. Johnson & Johnson (NYSE:JNJ) weekly performance is 1.34%. On last trading day company shares ended up $101.34. Johnson & Johnson (NYSE:JNJ) distance from 50-day simple moving average is 6.31%. Analysts mean target price for the company is $104.55.
Leave a Reply